Institutional
FCPM III SERVICES B.V.
CIK 0002013410
$722.2M
Reported AUM
10
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · FCPM III SERVICES B.V. · Q1 2026
AI · grounded in 13F
FCPM III SERVICES B.V. established a new position in DMRA valued at $63.2M. The fund closed its entire position in RAPT, reducing exposure by $62.1M. Additionally, the fund increased its holdings in VOR by 13.8% and trimmed its stake in DYN by 15%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $27.91 | -0.25% | 31.16% | 188.92% | $294.5M | 40.77% | — | HELD |
| 2 | DYN | DYNE THERAPEUTICS INC | $25.10 | -3.09% | 158.01% | 53.16% | $84.2M | 11.66% | — | HELD |
| 3 | VOR | VOR BIOPHARMA INC | $19.55 | -2.25% | -52.38% | -93.19% | $73.5M | 10.17% | — | HELD |
| 4 | — | ENGENE HOLDINGS INC | — | — | — | — | $65.6M | 9.08% | — | HELD |
| 5 | MPLT | MAPLIGHT THERAPEUTICS INC | $15.02 | 22.01% | -27.25% | -9.68% | $65.6M | 9.08% | — | HELD |
| 6 | DMRA | DAMORA THERAPEUTICS INC | $28.33 | -3.70% | 783.93% | -74.53% | $63.2M | 8.75% | — | HELD |
| 7 | CBIO | CRESCENT BIOPHARMA INC. | $14.77 | -10.16% | 23.08% | -106.05% | $30.8M | 4.27% | — | HELD |
| 8 | REPL | REPLIMUNE GROUP INC | $5.41 | 1.12% | -28.82% | -82.97% | $21.5M | 2.97% | — | HELD |
| 9 | BCYC | BICYCLE THERAPEUTICS PLC | $3.86 | -2.03% | -51.69% | -89.19% | $16.1M | 2.23% | — | HELD |
| 10 | — | ENGENE HOLDINGS INC | — | — | — | — | $7.3M | 1.01% | — | HELD |
Source: SEC EDGAR · accession 0001193125-26-225423. 13F discloses long positions only — shorts, foreign equities, and options are excluded.